Drug Type Antibody drug conjugate (ADC) |
Synonyms CKD 703, CKD703 |
Target |
Action inhibitors, modulators |
Mechanism Tubulin inhibitors, c-Met modulators(Hepatocyte growth factor receptor modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 16 Apr 2026 | |
| c-Met positive non-small cell lung cancer | Phase 2 | United States | 16 Apr 2026 | |
| MET gene amplification Non-small Cell Lung Cancer | Phase 2 | United States | 16 Apr 2026 | |
| Neoplasms | Phase 1 | South Korea | - |






